Agarwal K, et al. - This study was initiated in order to inspect the 96 weeks therapeutic outcomes of tenofovir alafenamide (TAF) vs. tenofovir disoproxil fumarate (TDF) for hepatitis B virus HBV infection. It was deduced that TAF and TDF were equally effective in patients with HBV infection. Both the therapies led to continued improvement in the renal and bone safety, two years after the initiation of treatment.